{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:11:33Z","timestamp":1761513093856},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T00:00:00Z","timestamp":1329436800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Anal Bioanal Chem"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s00216-012-5802-4","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T13:00:59Z","timestamp":1329397259000},"page":"1823-1830","source":"Crossref","is-referenced-by-count":8,"title":["Development and validation of a GC-EI-MS method with reduced adsorption loss for the quantification of olanzapine in human plasma"],"prefix":"10.1007","volume":"403","author":[{"given":"Kayo","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Kozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Yokoshige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,17]]},"reference":[{"key":"5802_CR1","first-page":"87","volume":"77","author":"RW Fuller","year":"1992","unstructured":"Fuller RW, Snoddy HD (1992) Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 77:87\u201393","journal-title":"Res Commun Chem Pathol Pharmacol"},{"key":"5802_CR2","first-page":"81","volume":"25","author":"K Kassahun","year":"1997","unstructured":"Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L (1997) Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 25:81\u201393","journal-title":"Drug Metab Dispos"},{"key":"5802_CR3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177\u2013193","journal-title":"Clin Pharmacokinet"},{"key":"5802_CR4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/00498258409151404","volume":"14","author":"AR Boobis","year":"1984","unstructured":"Boobis AR, Davies DS (1984) Human cytochromes P-450. Xenobiotica 14:151\u2013185","journal-title":"Xenobiotica"},{"key":"5802_CR5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.1991.8","volume":"49","author":"W Kalow","year":"1991","unstructured":"Kalow W, Tang BK (1991) Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49:44\u201348","journal-title":"Clin Pharmacol Ther"},{"key":"5802_CR6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2125.1988.tb03393.x","volume":"26","author":"D Sesardic","year":"1988","unstructured":"Sesardic D, Boobis AR, Edwards RJ, Davies DS (1988) A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26:363\u2013372","journal-title":"Br J Clin Pharmacol"},{"key":"5802_CR7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1176\/ajp.150.4.546","volume":"150","author":"AH Glassman","year":"1993","unstructured":"Glassman AH (1993) Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 150:546\u2013553","journal-title":"Am J Psychiatry"},{"key":"5802_CR8","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1001\/jama.284.20.2606","volume":"284","author":"K Lasser","year":"2000","unstructured":"Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH (2000) Smoking and mental illness: a population-based prevalence study. JAMA 284:2606\u20132610","journal-title":"JAMA"},{"key":"5802_CR9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00000441-200310000-00014","volume":"326","author":"D Ziedonis","year":"2003","unstructured":"Ziedonis D, Williams JM, Smelson D (2003) Serious mental illness and tobacco addiction: a model program to address this common but neglected issue. Am J Med Sci 326:223\u2013230","journal-title":"Am J Med Sci"},{"key":"5802_CR10","doi-asserted-by":"crossref","first-page":"940","DOI":"10.5649\/jjphcs.32.940","volume":"32","author":"H Sato","year":"2006","unstructured":"Sato H, Maruyama T, Otagiri Y, Mimura E, Kawakami K, Ikeda R, Okayama Y, Anraku M, Otagiri M (2006) Evaluation of usefulness of population pharmacokinetics analysis results to community pharmacy: effects of smoking and gender difference on olanzapine dosages. Jpn J Pharm Health Care Sci 32:940\u2013945","journal-title":"Jpn J Pharm Health Care Sci"},{"key":"5802_CR11","unstructured":"Ministry of Health Labour and Welfare (2003) The National Nutrition Survey, Japan:NNS-J. http:\/\/www.mhlw.go.jp\/houdou\/2005\/04\/h0421-1.html . Accessed 29 Oct 2011"},{"key":"5802_CR12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/cpt1976195part1546","volume":"19","author":"SN Hunt","year":"1976","unstructured":"Hunt SN, Jusko WJ, Yurchak AM (1976) Effect of smoking on theophylline disposition. Clin Pharmacol Ther 19:546\u2013551","journal-title":"Clin Pharmacol Ther"},{"key":"5802_CR13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.7326\/0003-4819-106-4-553","volume":"106","author":"BL Lee","year":"1987","unstructured":"Lee BL, Benowitz NL, Jacob P 3rd (1987) Cigarette abstinence, nicotine gum, and theophylline disposition. Ann Intern Med 106:553\u2013555","journal-title":"Ann Intern Med"},{"key":"5802_CR14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.04.003","volume":"76","author":"MS Faber","year":"2004","unstructured":"Faber MS, Fuhr U (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 76:178\u2013184","journal-title":"Clin Pharmacol Ther"},{"key":"5802_CR15","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00007691-200208000-00010","volume":"24","author":"E Skogh","year":"2002","unstructured":"Skogh E, Reis M, Dahl M-L, Lundmark J, Bengtsson F (2002) Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 24:518\u2013526","journal-title":"Ther Drug Monit"},{"key":"5802_CR16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0378-4347(95)00061-M","volume":"668","author":"JT Catlow","year":"1995","unstructured":"Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP (1995) Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B 668:85\u201390","journal-title":"J Chromatogr B"},{"key":"5802_CR17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/00007691-199706000-00011","volume":"19","author":"M Aravagiri","year":"1997","unstructured":"Aravagiri M, Ames D, Wirshing WC, Marder SR (1997) Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther Drug Monit 19:307\u2013313","journal-title":"Ther Drug Monit"},{"key":"5802_CR18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0378-4347(00)00438-2","volume":"750","author":"MA Raggi","year":"2001","unstructured":"Raggi MA, Casamenti G, Mandrioli R, Volterra V (2001) A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure. J Chromatogr B 750:137\u2013146","journal-title":"J Chromatogr B"},{"key":"5802_CR19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jchromb.2003.11.037","volume":"802","author":"Z Zhou","year":"2004","unstructured":"Zhou Z, Li X, Li K, Xie Z, Cheng Z, Peng W, Wang F, Zhu R, Li H (2004) Simultaneous determination of clozapine, olanzapin, risperidon and quetiapine in plasma by high-performance liquid chromatography\u2013electrospray ionization mass spectrometry. J Chromatogr B 802:257\u2013262","journal-title":"J Chromatogr B"},{"key":"5802_CR20","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jpba.2004.01.005","volume":"35","author":"C Chin","year":"2004","unstructured":"Chin C, Zhang ZP, Karnes HT (2004) A study of matrix effects on an LC\/MS\/MS assay for olanzapine and desmethyl olanzapine. J Pharm Biomed Anal 35:1149\u20131167","journal-title":"J Pharm Biomed Anal"},{"key":"5802_CR21","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jpba.2006.01.040","volume":"41","author":"RVS Nirogi","year":"2006","unstructured":"Nirogi RVS, Kandikere VN, Shukla M, Mudigonda K, Maurya S, Boosi R, Yerramilli A (2006) Development and validation of a sensitive liquid chromatography\/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma. J Pharm Biomed Anal 41:935\u2013942","journal-title":"J Pharm Biomed Anal"},{"key":"5802_CR22","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jpba.2010.03.040","volume":"53","author":"M Josefsson","year":"2010","unstructured":"Josefsson M, Roman M, Skogh E, Dahl ML (2010) Liquid chromatography\/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid. J Pharm Biomed Anal 53:576\u2013582","journal-title":"J Pharm Biomed Anal"},{"key":"5802_CR23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jms.440","volume":"38","author":"C Kratzsch","year":"2003","unstructured":"Kratzsch C, Peters FT, Kraemer T, Weber AA, Maurer HH (2003) Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography\/mass spectrometry with atmospheric pressure chemical ionization. J Mass Spectrom 38:283\u2013295","journal-title":"J Mass Spectrom"},{"key":"5802_CR24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1520\/JFS2004067","volume":"50","author":"EL Horak","year":"2005","unstructured":"Horak EL, Jenkins AJ (2005) Postmortem tissue distribution of olanzapine and citalopram in a drug intoxication. J Forensic Sci 50:679\u2013681","journal-title":"J Forensic Sci"},{"key":"5802_CR25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00000433-200109000-00014","volume":"22","author":"TC Merrick","year":"2001","unstructured":"Merrick TC, Felo JA, Jenkins AJ (2001) Tissue distribution of olanzapine in a postmortem case. Am J Forensic Med Pathol 22:270\u2013274","journal-title":"Am J Forensic Med Pathol"},{"key":"5802_CR26","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jat\/22.7.605","volume":"22","author":"AJ Jenkins","year":"1998","unstructured":"Jenkins AJ, Sarconi KM, Raaf HN (1998) Determination of olanzapine in a postmortem case. J Anal Toxicol 22:605\u2013609","journal-title":"J Anal Toxicol"},{"key":"5802_CR27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/bmc.1073","volume":"22","author":"WR Aasim","year":"2008","unstructured":"Aasim WR, Gan SH, Tan SC (2008) Development of a simultaneous liquid-liquid extraction and chiral derivatization method for stereospecific GC-MS analysis of amphetamine-type stimulants in human urine using fractional factorial design. Biomed Chromatogr 22:1035\u20131042","journal-title":"Biomed Chromatogr"},{"key":"5802_CR28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1248\/jhs.53.53","volume":"53","author":"I Saito","year":"2007","unstructured":"Saito I, Seto H (2007) Measurement of nicotine in indoor air collected by alkaline-coated solid phase cartridge followed by GC-MS analysis. J Health Sci 53:53\u201359","journal-title":"J Health Sci"},{"key":"5802_CR29","unstructured":"Food and Drug Administration (2001) Guidance for industry: bioanalytical method validation, May 2001. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070107.pdf . Accessed 29 Oct 2011"},{"key":"5802_CR30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jms.1783","volume":"45","author":"E Saar","year":"2010","unstructured":"Saar E, Gerostamoulos D, Drummer OH, Beyer J (2010) Identification and quantification of 30 antipsychotics in blood using LC-MS\/MS. J Mass Spectrom 45:915\u2013925","journal-title":"J Mass Spectrom"},{"key":"5802_CR31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/jat\/33.4.212","volume":"33","author":"MK Nielsen","year":"2009","unstructured":"Nielsen MK, Johansen SS (2009) Determination of olanzapine in whole blood using simple protein precipitation and liquid chromatography-tandem mass spectrometry. J Anal Toxicol 33:212\u2013217","journal-title":"J Anal Toxicol"}],"container-title":["Analytical and Bioanalytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-012-5802-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00216-012-5802-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-012-5802-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T20:48:20Z","timestamp":1558644500000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00216-012-5802-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,17]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["5802"],"URL":"https:\/\/doi.org\/10.1007\/s00216-012-5802-4","relation":{},"ISSN":["1618-2642","1618-2650"],"issn-type":[{"value":"1618-2642","type":"print"},{"value":"1618-2650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,17]]}}}